The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra‐Abdominal Infections: Analysis of Pooled Clinical Trial Data
Abstract
This pooled analysis includes 2 phase 3, double-blind trials designed to evaluate the safety and efficacy of tigecycline, versus that of imipenem-cilastatin, in 1642 adults with complicated intra-abdominal infections. Patients were randomized to receive either tigecycline (initial dose of 100 mg, followed by 50 mg intravenously every 12 h) or imipenem-cilastatin (500/500 mg intravenously every 6 h) for 5-14 days. The primary end point was the clinical response at the test-of-cure visit (12-42 days after therapy) in the co-primary end point microbiologically evaluable and microbiological modified intent-to-treat populations. For the microbiologically evaluable group, clinical cure rates were 86.1% (441/512) for tigecycline, versus 86.2% (442/513) for imipenem-cilastatin (95% confidence interval for the difference, -4.5% to 4.4%; P < .0001 for noninferiority). Clinical cure rates in the microbiological modified intent-to-treat population were 80.2% (506/631) for tigecycline, versus 81.5% (514/631) for imipenem-cilastatin (95% confidence interval for the difference, -5.8% to 3.2%; P < .0001 for noninferiority). Nausea (24.4% tigecycline, 19.0% imipenem-cilastatin [P = .01]), vomiting (19.2% tigecycline, 14.3% imipenem-cilastatin [P = .008]), and diarrhea (13.8% tigecycline, 13.2% imipenem-cilastatin [P = .719]) were the most frequently reported adverse events. This pooled analysis demonstrates that tigecycline was efficacious and well tolerated in the treatment of patients with complicated intra-abdominal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard
Wikler, M. A., & Clinical (2012) · Medical Entomology and Zoology · Cited by 895
Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections
Solomkin, J. S., Mazuski, J. E., Baron, E. J., Sawyer, R. G., Nathens, A. B., DiPiro, J. T., Buchman, T., Dellinger, E. P., Jernigan, J., Gorbach, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/378702 · Cited by 515
Petersen, P. J., Jacobus, N. V., Weiss, W. J., Sum, P. E., & Testa, R. T. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.738 · Cited by 415
The Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Henwood, C. J., Gatward, T., Warner, M., James, D., Stockdale, M. W., Spence, R. P., Towner, K. J., Livermore, D. M., & Woodford, N. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.3.479 · Cited by 213
Gales, A. C., & Jones, R. N. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00092-9 · Cited by 189
Intensive care unit management of intra-abdominal infection
Marshall, J. C., & Innes, M. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000087326.59341.51 · Cited by 184
Burnett, R. J., Haverstock, D. C., Dellinger, E. P., Reinhart, H. H., Bohnen, J. M., Rotstein, O. D., Vogel, S. B., & Solomkin, J. S. (1995) · Surgery · doi:10.1016/s0039-6060(05)80040-6 · Cited by 173
Petersen, P. J., Bradford, P. A., Weiss, W. J., Murphy, T. M., Sum, P. E., & Projan, S. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2595-2601.2002 · Cited by 169
Krobot, K., Yin, D., Zhang, Q., Sen, S., Altendorf-Hofmann, A., Scheele, J., & Sendt, W. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1199-0 · Cited by 160
Cited by
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans
He, T., Wang, R., Liu, D., Walsh, T. R., Zhang, R., Lv, Y., Ke, Y., Ji, Q., Wei, R., Liu, Z., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0445-2 · Cited by 705
The role of antibiotics and antibiotic resistance in nature
Aminov, R. I. (2009) · Environmental Microbiology · doi:10.1111/j.1462-2920.2009.01972.x · Cited by 687
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac268 · Cited by 526
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1478 · Cited by 441
Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe
Souli, M., Galani, I., & Giamarellou, H. (2008) · Eurosurveillance · doi:10.2807/ese.13.47.19045-en · Cited by 436
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab295 · Cited by 390
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 388
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Antianaerobic Antimicrobials: Spectrum and Susceptibility Testing
Brook, I., Wexler, H. M., & Goldstein, E. J. C. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00086-12 · Cited by 333
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose
Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., & Ellis-Grosse, E. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl403 · Cited by 304
Self-citationTigecycline: A Critical Analysis
Stein, G. E., & Craig, W. A. (2006) · Clinical Infectious Diseases · doi:10.1086/505494 · Cited by 298
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Multidrug-Resistant Gram-Negative Infections: What are the Treatment Options?
Giamarellou, H., & Poulakou, G. (2009) · Drugs · doi:10.2165/11315690-000000000-00000 · Cited by 288
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Freire, A. T., Melnyk, V., Kim, M. J., Datsenko, O., Dzyublik, O., Glumcher, F., Chuang, Y.-C., Maroko, R. T., Dukart, G., Cooper, C. A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.05.012 · Cited by 284
Self-citationEfficacy and safety of tigecycline: a systematic review and meta-analysis
Yahav, D., Lador, A., Paul, M., & Leibovici, L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr242 · Cited by 266
Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis
Tasina, E., Haidich, A.-B., Kokkali, S., & Arvanitidou, M. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70177-3 · Cited by 260
Acinetobacter baumannii: a universal threat to public health?
Giamarellou, H., Antoniadou, A., & Kanellakopoulou, K. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.02.013 · Cited by 258
Metadata
- Authors
- Babinchak, T., Ellis‐Grosse, E., Dartois, N., Rose, G. M., Loh, E., & Groups, T. 3. A. 3. S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09
- Volume
- 41
- Issue
- s5
- Pages
- S354-S367
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2137408524
- Cited by
- 381
- References
- 14
- FWCI
- 21.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.